An FDA advisory committee began priming the pipeline Wednesday for new hepatitis C virus (HCV) treatments, voting unanimously to recommend approval of Merck & Co. Inc.'s boceprevir in conjunction with the current standard of care (SOC), pegylated interferon and ribavirin, to treat chronic HCV genotype 1.